导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 26.70% | 202/4773 |
| 近一周 | 1.14% | 473/5465 |
| 近一月 | -5.35% | 3730/5421 |
| 近一季 | -12.41% | 4036/5231 |
| 近半年 | 23.82% | 131/4920 |
| 近一年 | 30.13% | 244/4394 |
| 近两年 | 165.25% | 169/2954 |
| 近三年 | 114.53% | 118/2253 |
| 成立以来 | 100.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.82% 3431/4961 |
78.67% 181/5312 |
- - |
- - |
| 2025 | 51.79% 426/4813 |
-0.04% 2034/3635 |
3.76% 952/4076 |
51.93% 266/4524 |
-3.67% 3316/4813 |
| 2024 | 11.98% 1284/3463 |
-4.93% 1803/2808 |
-4.73% 1545/3014 |
16.20% 1509/3129 |
6.40% 518/3463 |
| 2023 | 0.78% 389/2656 |
16.30% 201/2280 |
-2.04% 555/2385 |
-9.98% 1925/2515 |
-1.74% 366/2655 |
| 2022 | -34.19% 1714/2207 |
-21.46% 1628/1919 |
-4.69% 1858/2016 |
-16.62% 1479/2113 |
5.43% 466/2208 |
| 2021 | -2.93% 880/1822 |
-9.07% 1100/1255 |
14.64% 248/1330 |
-12.29% 1301/1466 |
6.16% 231/1822 |
| 2020 | 44.31% 229/1250 |
3.57% 114/1028 |
27.57% 128/1067 |
0.20% 1044/1164 |
8.99% 653/1184 |
| 2019 | - - |
- - |
- - |
- - |
10.78% 97/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 华富中证港股通创新药指数型发起式A | 1.1464 | 27.24% |
| 嘉实中证港股通创新药指数发起式C | 0.8441 | 26.80% |
| 中欧中证港股通创新药指数发起A | 1.5868 | 26.75% |
| 中欧中证港股通创新药指数发起C | 1.4370 | 26.67% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8762 | 26.58% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8585 | 26.45% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8568 | 26.39% |
| 华宝中证科技龙头ETF VS. 长安沪深300非周期A(740101) |